# Citations for Research Query

**Query:** # Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Maple Syrup Urine Disease
- **MONDO ID:**  (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Maple Syrup Urine Disease**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs

**Provider:** falcon
**Generated:** 2026-01-08T14:52:09.311447

1. pontoizeau2022neonatalgenetherapy pages 1-2
2. singh2024computationalstructuralgenomics pages 1-2
3. huang2025branchedchainaminoacids pages 4-5
4. muelly2013biochemicalcorrelatesof pages 7-10
5. sonnet2016metformininhibitsbranched pages 9-10
6. fermo2023branchedchainaminoacids pages 1-2
7. sonnet2016metformininhibitsbranched pages 1-3
8. yang2024genotypicandphenotypic pages 11-12
9. brunettipierri2011phenylbutyratetherapyfor pages 1-2
10. alili2022intravenousadministrationof pages 1-2
11. baidya2024maplesyrupurine pages 6-6
12. rezaie2024acomprehensivein pages 12-12
13. Î±-ketoisocaproic acid
14. https://doi.org/10.1038/s41467-022-30880-w;
15. https://doi.org/10.1002/jmd2.12419;
16. https://doi.org/10.3390/ijms26146992;
17. https://doi.org/10.1172/jci67217;
18. https://doi.org/10.1091/mbc.11.5.1919;
19. https://doi.org/10.1101/2023.07.31.551364;
20. https://doi.org/10.1007/s11011-022-01109-y;
21. https://doi.org/10.1038/srep28775;
22. https://doi.org/10.1093/qjmed/hcae104;
23. https://doi.org/10.1186/s13023-024-03411-7;
24. https://doi.org/10.1093/hmg/ddq507;
25. https://doi.org/10.3390/nu16183145;
26. https://doi.org/10.1186/s13023-022-02353-2;
27. https://doi.org/10.12659/aot.939893;
28. https://doi.org/10.3389/fimmu.2025.1579945;
29. https://doi.org/10.1038/s41467-022-30880-w,
30. https://doi.org/10.1002/jmd2.12419,
31. https://doi.org/10.3390/ijms26146992,
32. https://doi.org/10.1172/jci67217,
33. https://doi.org/10.1038/srep28775,
34. https://doi.org/10.1007/s11011-022-01109-y,
35. https://doi.org/10.1093/qjmed/hcae104,
36. https://doi.org/10.22099/mbrc.2024.49847.1958,
37. https://doi.org/10.1186/s12887-024-05266-0,
38. https://doi.org/10.1093/hmg/ddq507,
39. https://doi.org/10.1186/s13023-022-02353-2,